Hyderabad, Aug. 17 -- The US Food and Drug Administration (USFDA) has classified the Raleigh plant in North Carolina, USA, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of Aurobindo Pharma Limited, as "Voluntary Action Indicated" (VAI) following an inspection conducted between March 24 and April 10, 2025.
The Hyderabad based pharma company informed the stock exchanges on Monday that the Raleigh facility, which manufactures inhalers, dermatology and transdermal products, was issued Form 483 with a total of 11 observations at the end of the inspection.
The facility has now received the Establishment Inspection Report (EIR), with the USFDA classifying the inspection as VAI and concluding the inspection process.
Aurobindo...